Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional “3 + 7” intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial

Key Points

• To compare the efficacy and safety of the ABC-14 regimen against traditional treatment approaches for newly diagnosed AML patients.
• Prospective, multicenter, randomized, open-label clinical trial design
• Participants include newly diagnosed acute myeloid leukemia (AML) patients
• Interventions involve the ABC-14 regimen and traditional induction regimens
• Evaluation of efficacy and safety outcomes between the ABC-14 and 3 + 7 regimens
• Potential identification of superior treatment strategies for AML